Company / Capital Expenditures
Incyte Capital Expenditures History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$48.7M
FY2024
5-year range
$48.7M / $181.0M
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#28 of 194
Health Care
What the data says
Incyte's capital expenditures of $49M is higher than 86% of companies in the Health Care sector (FY2024). Capital Expenditures has fluctuated over the past 8 years, ranging from $49M in FY2024 to $181M in FY2021.
Based on SEC 10-K filings.
$49M in FY2024 with a 5-year CAGR of -15.2%. Top quartile in the Health Care sector.
Declined from $181M to $49M over the past 3 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -35.4%
- 5-Year CAGR
- -15.2%
- 10-Year CAGR
- -
Sector benchmark
-58.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.2%, indicating a declining trend.
- Ranks #28 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.7%
- Strong return on equity: 25.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $48.7M | - |
| FY2023 | - | - |
| FY2022 | $77.8M | -57.0% |
| FY2021 | $181.0M | +146.3% |
| FY2020 | $73.5M | -33.8% |
| FY2019 | $111.0M | +51.1% |
| FY2018 | $73.5M | -33.8% |
| FY2017 | $111.0M | -7.7% |
| FY2016 | $120.3M | +362.6% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026